



Drug Use Research & Management Program

OHA Health Systems Division

500 Summer Street NE, E35; Salem, OR 97301-1079

College of Pharmacy

Phone 503-947-5220 | Fax 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, June 6th, 2024

1:00 PM - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence, and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee, and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Brandon Wells; Dee Weston, JD; Trevor Douglass, DC; Jennifer Bowen; Michael Yu; Kyle Hamilton

Audience: Kristal Hartman*, Obesity Action Coalition; Jaymey Sweeny*, OHSU/ Novo Nordisk; Kat Khachatourian*, Novo Nordisk; Josh Akers*, Eli Lilly; Kaysen Bala*, Blubird Bio; Chad Duncan*, Vertex; Nirmal Ghuman*, J&J; Ronnie DePue*, Axsome Therapeutics; Lynda Finch*, Biogen; Chris Brain-Hernandez, PGY-1 Resident Samaritan; James Templeton, Astellas; Melissa Bailey Hall, Lilly; Josie Altman, Dalton Advocacy; Mariah Scott, Sickle Cell Advocacy; Sabrina Riggs, Novo Nordisk; Devin Pence, Vertex; Nancy Ouzziferri, OHSU; Matt Worthy, OHSU; Rogue Hartman, OSU/OHSU Pharmacy Student; Dan O'Donnell, Axsome; Bill McDougall, Biogen; Elena Fernandez, Vertex; Lisa Pulver, J&J; Jason Morris, Samaritan; Norm Navarro, Providence; Lori Howarth, Bayer; Kim Eggert; Suzanne Stewart; Amanda Cramer, IHN; Paul Ford, J&J; Mark Kantor, AllCare; Courtne Holmes, CareOregon; Susan Manns; Drew Larson, OHSU; Georgette Dzwilewski; Britt Manning; Trish Wong, OHSU; Leif Bruce, Novo Nordisk; Brandie Ferger, Advanced Health; Chris Ferrin, IHN; Tiina Andrews, UHA; Mark England, Mercer

(*) Provided verbal testimony

I. CALL TO ORDER

- A. Roll Call & Introductions
 - Called to order at approx. 1:05 p.m., introductions by Committee and staff
- B. Conflict of Interest Declaration – no new conflicts of interest were declared
- C. Approval of Agenda and April 2024 Minutes presented by Roger Citron, RPh
ACTION: Motion to approve, 2nd, all in favor
- D. Department Update provided by Andrew Gibler, PharmD

II. CONSENT AGENDA TOPICS

- A. Quarterly Utilization Report
- B. Insulin Class Literature Scan
Recommendation:
 - No changes to the Preferred Drug List (PDL) are recommended based on the clinical review of efficacy and safety
 - Evaluate costs in executive session
- C. PDL Old Business: Inhalers for Asthma and COPD Class Update
Recommendation:
 - No new evidence was being considered to recommend PDL changes
 - Evaluate costs in executive session
- D. Oncology Prior Authorization (PA) Updates
Recommendation:
 - Add: Tevimbra[®] (tislelizumab-jsgr) to Table 1 in the Oncology Agents PA criteria**ACTION: Motion to approve, 2nd, all in favor**

III. DUR ACTIVITIES

- A. ProDUR Report: Lan Starkweather, PharmD
- B. RetroDUR Report: Dave Engen, PharmD
- C. Oregon State Drug Review: Kathy Sentena, PharmD
 - 1. Opioid Reversal Agents
 - 2. Updates for Insomnia: Evidence and Oregon Medicaid Policy

IV. DUR NEW BUSINESS

- A. Attention Deficit Hyperactivity Disorder Drug Utilization Evaluation and Policy
Evaluation: Sarah Servid, PharmD
Recommendation:

- Update PA criteria to permit off-label use of non-stimulant ADHD drugs upon consultation with a mental health provider
 - Remove age restrictions for extended-release 12H clonidine and extended-release guanfacine to permit off-label use in adults
- ACTION:** The Committee recommended removing PA altogether: make agents preferred and remove age and quantity limits
- Motion to approve, 2nd, all in favor**

B. Drugs for Weight Loss Prior Authorization Update: Kathy Sentena, PharmD

Recommendations:

- Implement the PA criteria for Wegovy® (semaglutide) as proposed to ensure appropriate use in people with overweight and obesity who are 45 years of age and older for secondary prevention of major cardiovascular events

Public Comment: Kristal Hartman, Obesity Action Coalition; Jaymey Sweeny, S. Oregon Bariatric Center/OHSU, and Novo Nordisk; Kat Khachatourian, Novo Nordisk; Josh Akers, Eli Lilly

ACTION: Motion to approve, 2nd, all in favor

SUBSEQUENT ACTION: There was a Motion and 2nd to remove the age restriction altogether from the approved criteria that did not pass

V. PREFERRED DRUG LIST (PDL) NEW BUSINESS

A. Pompe Disease Class Update and New Drug Evaluation (NDE): David Engen, PharmD

Recommendations:

- Implement the proposed PA criteria for cipaglucoasidase alfa and miglustat combination therapy as proposed
- Evaluate costs in executive session

ACTION: The Committee recommended removing question #3 in the proposed criteria

Motion to approve, 2nd, all in favor

B. Gabipentinoids, Off-label Indication Review: Megan Herink, PharmD

Recommendations:

- Modify Pregabalin PA to allow use of for generalized anxiety disorder in those who have trialed or have a contraindication to first line treatment with a SSRI and SNRI without a prior trial of gabapentin

ACTION: Motion to approve, 2nd, all in favor

C. Gene Therapy for Sickle Cell Disease & Beta Thalassemia NDEs: Sara Fletcher, PharmD

Recommendations:

- Implement the proposed PA criteria to ensure safe and appropriate use of gene therapy for SCD and TDT

- Maintain exagamglogene autotemcel and lovetibeglogene autotemcel as non-preferred

Public Comment: Kaysen Bala, Bluebird Bio; Chad Duncan, Vertex

ACTION: Motion to approve, 2nd, all in favor

D. Antidepressants Class Update with NDE: Kathy Sentena, PharmD

Recommendations:

- No changes to the PDL are recommended based on the clinical review of recent literature

- Maintain gepirone as voluntary non-preferred on the PDL

- Update Tricyclic Antidepressant PA based on Mental Health Clinical Advisory Group recommendations

- Evaluate costs in executive session

Public Comment: Ronnie DePue, Axsome Therapeutics; Nirmal Ghuman, J&J; Lynda Finch, Biogen

ACTION: Motion to approve, 2nd, all in favor

E. Veozah™ (fezolinetant) NDE: Deanna Moretz, PharmD

Recommendations:

- Add fezolinetant to the PDL and designate as non-preferred

- Implement proposed PA criteria

ACTION: Motion to approve, 2nd, all in favor

VI. EXECUTIVE SESSION

Members Present: Stacy Ramirez, PharmD; Patrick DeMartino, MD; Bridget Bradley, PharmD; Douglas Carr, MD; Russ Huffman, PMHNP; Tim Langford, PharmD; Cat Livingston, MD; Eriko Onishi, MD; Eddie Saito, PharmD; Samara Stevens, ND

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Andrew Gibler, PharmD; Megan Herink, PharmD; Deanna Moretz, PharmD; Kathy Sentena, PharmD; Sarah Servid, PharmD; Lan Starkweather, PharmD; Dee Weston; Kyle Hamilton

VII. RECONVENE for PUBLIC RECOMMENDATIONS

A. Insulin Class Literature Scan

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

B. Inhalers for Asthma and COPD

Make Qvar Redihaler[®] (beclomethasone dipropionate HFA) and Asmanex[®] HFA (momentasone HFA) preferred; and fluticasone propionate HFA non-preferred

ACTION: Motion to approve, 2nd, all in favor

C. Pompe Disease

Make no changes to the PDL

ACTION: Motion to approve, 2nd, all in favor

D. Antidepressants

Assign voluntary nonpreferred status to trazodone, Zulresso[®] (brexanolone) and Symbyax[®] (olanzapine/fluoxetine HCL)

ACTION: Motion to approve, 2nd, all in favor

VIII. ADJOURN